In 1989 Bristol-Myers Squibb Co. was selected by NCI as a CRADA partner to commercialize the drug.

• 约翰霍普金斯大学医学院报道了紫杉醇对晚期卵巢癌的惊人疗效并被1989年的国内医药学年鉴收录。